Matuzumab

Drug Profile

Matuzumab

Alternative Names: Anti-EGFR monoclonal antibody; EMD 72000

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator ImClone Systems
  • Developer Merck KGaA; Takeda
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 30 May 2013 Biomarkers information updated
  • 20 Feb 2008 Takeda together with Merck have decided to jointly discontinue development of matuzumab for all indications
  • 20 Feb 2008 Discontinued - Phase-II for Cervical cancer in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top